Nucala
This is real life

Real world studies now support the findings of RCTs which prove the efficacy of Nucala in adults with severe eosinophilic asthma.1,2

This is a fictional patient for illustrative purposes

Nucala (mepolizumab) is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older. The licensed dose of Nucala in children aged 6-11 years is 40mg SC.1

Nucala is the only anti-IL-5 to demonstrate long-term reduction in exacerbations and OCS dose for up to 4.8 years.2,3

REALITI-A real-world study in adults2

REALITI-A is an ongoing 24-month, international, prospective, single-arm, observational cohort study enrolling patients aged 18 years and over with severe asthma and recently prescribed mepolizumab 100mg SC once every 4 weeks at physician’s discretion.2

The data below is an interim analysis of the early initiators with 12 months of data.

Nucala Nucala

Ratio rate: 0.31 95% CI:0.27-0.35 p<0.001
Baseline rate/year: 4.63
12 months post-Nucala rate/year: 1.43
Absolute rate/year reduction: 3.2

Nucala Nucala

95% CI: 50-75
Baseline | 10mg
At 12 months | 5mg
 

Results are descriptive

52% is the median percent reduction from baseline in average daily dose of maintenance OCS.
Statistical significance not achieved. Study limitations: These data are a prespecified interim analysis of 368 patients who completed 12 months of follow-up as of Feb 2019. This analysis may not reflect the results from the final dataset.

COSMEX long term study3

Could your patients benefit from reducing their OCS dose?

Nucala Nucala

Baseline | 11.3 mg/day
Week 128 | with Nucala 1.3 mg/day

COSMEX (4.8 year study) 88% reduction in OCS dose vs. baseline at 2.5 years. Results are descriptive. Study not powered for statistical significance.
The maximum exposure duration of mepolizumab in the phase 3 and open label extension studies was 4.8 years. A patient withdrawal range of 4 weeks to 4.8 years was observed in MENSA, SIRIUS, COSMOS and COSMEX
In total, 95 patients with ≥188 weeks of continuous reporting across MENSA, COSMOS and COSMEX with ≤12 weeks between the last dose in COSMOS and first dose in COSMEX are summarised (MENSA: placebo [n=24], Nucala [n=71]). The Nucala group in MENSA contains patients on both 100mg SC and 75mg IV doses (75mg IV dose is not an approved dose of Nucala). Analyses include clinically significant exacerbations from MENSA and all exacerbations from COSMOS and COSMEX.

Nucala: Mechanism of action

Nucala

Nucala: The power to choose at home or in clinic administration1

Nucala offers at-home administration that lets appropriate patients self-administer without the need to come into the clinic or hospital. Nucala is the only 4-weekly asthma biologic with a simple fixed dose.1

The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in a pre-filled pen, prefilled syringe or lyophilised powder. The licensed dose of Nucala in children aged 6-11 years is 40mg SC once every 4 weeks, regardless of weight, and available in lyophilised powder.

Identify and support patients with severe eosinophilic asthma

Identifying Patient

Identify patients with elevated eosinophil levels that are eligible for Nucala

Patient Support Material

Support for you and your patients when starting treatment with Nucala

References

  1. Nucala SmPC
  2. Harrison, T et al, 2020. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. European Respiratory Journal,56(4)
  3. Khurana S et al. Clin Ther 2019; 41:2041-2056

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

© 2021 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.

January 2022 | PM-GB-MPL-WCNT-200040 (V3.0)